Introduction
Materials and methods
Patients and tissue samples
Clinicopathological features | No.of cases | SOX9 expression | P | |
---|---|---|---|---|
High(n, %) | Low(n, %) | |||
Age
| ||||
<55 | 72 | 50 (69.4) | 22 (30.6) | NS |
≥55 | 94 | 70 (74.5) | 24 (25.5) | |
Gender
| ||||
Male | 96 | 70 (72.9) | 26 (27.1) | NS |
Female | 70 | 50 (71.4) | 20 (28.6) | |
Tumor size
(cm)
| ||||
>8 | 88 | 62 (70.5) | 26 (29.5) | NS |
≤8 | 78 | 58 (74.4) | 20 (25.6) | |
Anatomic location
| ||||
Tibia/femur | 103 | 76 (73.8) | 27 (26.2) | NS |
Elsewhere | 63 | 44 (69.8) | 19 (30.2) | |
Serum level of lactate dehydrogenase
| ||||
Elevated | 90 | 70 (77.8) | 20 (22.2) | NS |
Normal | 76 | 50 (65.8) | 26 (34.2) | |
Serum level of alkaline phosphatase
| ||||
Elevated | 108 | 80 (74.1) | 28 (25.9) | NS |
Normal | 58 | 40 (69.1) | 18 (30.9) | |
Clinical stage
| ||||
IIA | 68 | 32 (47.1) | 36 (52.9) | 0.02 |
IIB/III | 98 | 88 (89.8) | 10 (10.2) | |
Distant metastasis
| ||||
Absent | 124 | 78 (62.9) | 46 (37.1) | 0.008 |
Present | 42 | 42 (100.0) | 0 (0) | |
Response to chemotherapy
| ||||
Good | 68 | 32 (47.1) | 36 (52.9) | 0.02 |
Poor | 98 | 88 (89.8) | 10 (10.2) |
Real-time quantitative RT-PCR Assay
Western blot analysis
Immunohistochemistry analysis
Statistical analysis
Results
Upregulation of SOX9 at mRNA and protein levels in human osteosarcoma tissues
Upregulation of SOX9 protein associates with advanced clinicopathological features of osteosarcoma
Upregulation of SOX9 protein associates with poor prognosis in patients with osteosarcomas
Variables | OS | DFS | ||||
---|---|---|---|---|---|---|
RR | 95% CI | P | RR | 95% CI | P | |
SOX9 expression
| 6.9 | 1.5-14.8 | <0.001 | 6.1 | 1.3-13.9 | <0.001 |
Clinical stage
| 2.3 | 1.1-7.0 | 0.02 | 1.8 | 0.7-8.1 | 0.03 |
Distant metastasis status
| 3.7 | 1.9-9.8 | 0.01 | 2.9 | 1.3-10.6 | 0.02 |
Response to chemotherapy
| 2.6 | 1.5-8.2 | 0.02 | 0.9 | 0.3-1.7 | 0.6 |